Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops after cataract surgery may prevent blurring swelling

NCT ID NCT07696104

Prevention Sponsor: Pomeranian Medical University Szczecin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study compares four different anti-inflammatory eye drop schedules to prevent cystoid macular edema, a common cause of blurred vision after cataract surgery. About 88 adults having routine cataract surgery receive one of four NSAID regimens for 2 or 4 weeks after the procedure. Researchers measure retinal thickness and vision at 6 and 12 weeks to see which approach best prevents swelling.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bromfenac, Nepafenac, Diclofenac (NSAID eye drops)
What this could lead to
If one regimen works best, it could become the standard way to prevent post-cataract eye swelling, improving recovery and vision outcomes.
What could go wrong
This is a small, single-center trial with 88 participants, so results may not apply to everyone. NSAID eye drops can cause eye irritation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

88 people

The number who actually took part.

Started

Oct 2020

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults scheduled for elective uncomplicated phacoemulsification cataract surgery. 2. Ability and willingness to provide written informed consent. 3. No abnormalities detected on preoperative anterior segment examination. 4. No abnormalities detected on preoperative posterior segment examination. 5. Willingness and ability to attend follow-up visits at 6 and 12 weeks after cataract surgery. Exclusion Criteria: The exclusion criteria for the study were: 1. Systemic diseases that could affect the macula (e.g. diabetes). 2. Topical or systemic medications that could affect the macula, e.g. chloroquine. 3. Intraoperative complications. 4. Coexisting ocular diseases. 5. Previous ocular surgery. 6. Patients who. for various reasons. declared unwillingness to attend follow-up visits 6 and 12 weeks after cataract surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pseudophakic cystoid macular edema are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pseudophakic cystoid macular edema

Contacts and locations

Locations

  • University Clinical Hospital No. 2, Pomeranian Medical University in Szczecin

    Szczecin, 70-111, Poland